Search Results

You are looking at 1 - 10 of 13 items for :

  • DPP4 inhibitors x
  • All content x
Clear All
Open access

E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis, and K Kotsa

-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) inhibitor (sitagliptin) and cholecalciferol. Case presentation A 31-year-old Caucasian male was referred to

Open access

Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, and Margareth Afonso Torres

uncommon. In general terms, partial remission is defined as a daily requirement of insulin <0.5 IU/kg and levels of HbA1c <6% and stimulated C-peptide >0.90 ng/mL ( 4 , 5 ). Dipeptidyl peptidase 4 (DPP-4) inhibitors, such as sitagliptin, have been used

Open access

Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble, and Constantin Polychronakos

demonstrated that inhibitors of dipeptidyl peptidase 4 (DPP4) can diminish daily insulin requirements and improve metabolic control without exacerbating the risk of hypoglycemia in T1DM patients (7) (8) . However, as far as we are concerned, there has been

Open access

Murray B Gordon and Kellie L Spiller

optimal first-line antidiabetic medication ( 12 ). Metformin-based antidiabetic therapy can be intensified with the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor, such as sitagliptin. If necessary to achieve optimal glycemic control, the DPP-4

Open access

Jiman Kim, Eulsun Moon, and Seungwon Kwon

, is long-standing hypertensive diabetes mellitus, characterized pathophysiologically by glomerular hyperfiltration. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), both commonly used in preventing diabetic

Open access

Michelle Maher, Mohammed Faraz Rafey, Helena Griffin, Katie Cunningham, and Francis M Finucane

). Commercial meal replacement programmes have recently shown promise in managing T2DM ( 4 ), but side effects including constipation, dizziness, alopecia, nausea, headache, diarrhoea, abdominal pain and cholelithiasis are common ( 5 ), and these interventions

Open access

Senhong Lee, Aparna Morgan, Sonali Shah, and Peter R Ebeling

Background The rapid development of diabetic ketoacidosis after a single dose of an immune checkpoint inhibitor is extremely rare. This case highlights the importance of glycemic surveillance in patients receiving immune checkpoint inhibitors

Open access

Diana Catarino, Cristina Ribeiro, Leonor Gomes, and Isabel Paiva

of the immunosuppression induced by glucocorticoids ( 4 ), and such opportunistic infections result in high mortality for patients ( 5 ). Case presentation We describe the case of a 55-year-old Caucasian woman, working as poultry farmer, who

Open access

Elena Carrillo, Amparo Lomas, Pedro J Pinés, and Cristina Lamas

bilateral renal cyst and pelvic ecstasy are observed. Table 1 Initial analytic parameters. Parameter Value Reference interval Glycaemia (mg/dL) 717 74–109 HbA1c (%) 13 4–6 pH 7.42 7

Open access

Rajesh Rajendran, Sarita Naik, Derek D Sandeman, and Azraai B Nasruddin

literature search revealed 15 possible cases of pituitary adenomas secreting both ACTH and GH (2) (3) (4) (5) (6) (7) (8) . This cannot be confirmed in five of these cases, due to unavailability of modern immunohistochemistry techniques (2) (3